11/12/2013 8:52:28 AM
SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc., (NASDAQ: NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced the availability of the nCounter® Dx Analysis System for high-complexity, CLIA-certified laboratories. The nCounter Dx Analysis System is the only platform 510(k) cleared by the U.S. Food and Drug Administration to run the Prosigna™ Prognostic Breast Cancer Gene Signature Assay. For clinical laboratories that value flexibility, the FLEX configuration offered on the nCounter Dx Analysis System supports other translational research applications, and facilitates the ability of laboratories to develop their own assays. NanoString will showcase the new nCounter Dx Analysis System and its advanced capabilities at this week’s annual Association for Molecular Pathology (AMP) conference in Phoenix, Arizona.
Help employers find you! Check out all the jobs and post your resume.
comments powered by